ConnectOne Bancorp Strengthens Executive Leadership By Appointing Legal Advisor Robert Schwartz to General Counsel
ENGLEWOOD CLIFFS, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- ConnectOne Bancorp, Inc. (Nasdaq: CNOB) (the "Company" or "ConnectOne"), parent company of ConnectOne Bank (the "Bank"), announced the appointment of Robert A. Schwartz as General Counsel, effective June 1, 2025. This strategic appointment reinforces ConnectOne's commitment to strengthening executive leadership capabilities as it accelerates growth following the successful completion of its merger with First of Long Island Corporation (formerly Nasdaq: FLIC).
A recognized leader in the banking industry with deep expertise in mergers and acquisitions, securities law, and bank regulatory frameworks, Schwartz brings decades of legal and strategic experience to ConnectOne. In this role, he will advise the Board of Directors and executive leadership on legal, regulatory and business risks in an evolving operating environment. The appointment comes at a pivotal time for ConnectOne, as the Company recently reached nearly $14 billion in assets.
Schwartz has served as a trusted legal advisor to ConnectOne since its inception, playing a foundational role in the Bank's formation, IPO and multiple transactions throughout its 20-year history.
"Mr. Schwartz has been an integral player to the bank since day one, and we look forward to working with him in this new capacity," said Frank Sorrentino III, ConnectOne's Chairman & CEO. "His ability to balance legal acumen with business strategy will be instrumental in driving the success of the newly expanded institution as we prepare for our next chapter of growth. Bringing someone of his caliber in-house reflects the strength of our platform and our focus on building an industry-leading leadership team."
"After two decades of helping ConnectOne navigate many major milestones—from our formation to our IPO to strategic acquisitions—I'm energized to now lead our legal strategy from within," said Schwartz. "This transition from trusted advisor to executive team member is a testament to ConnectOne's ambitious vision. Together, we're positioned to capitalize on the growing opportunities in today's dynamic banking landscape."
Prior to joining the bank, Schwartz served as a Partner at Windels Marx, where he specialized in advising financial institutions on mergers and acquisitions, and bank regulatory and securities law. Schwartz holds a J.D. from Fordham Law School and a B.A. from Fordham University. He is a member of both the New Jersey and New York Bar.
About ConnectOne Bancorp, Inc.
ConnectOne Bancorp, Inc., is a modern financial services company that operates, through its subsidiary, ConnectOne Bank, and the Bank's fintech subsidiary, BoeFly, Inc. ConnectOne Bank is a high-performing commercial bank offering a full suite of banking & lending products and services that focus on small to middle-market businesses. BoeFly, Inc. is a fintech marketplace that connects borrowers in the franchise space with funding solutions through a network of partner banks. ConnectOne Bancorp, Inc. is traded on the Nasdaq Global Market under the trading symbol "CNOB," and information about ConnectOne may be found at https://www.connectonebank.com.
Investor Contact:
Media Contact:
Shannan Weeks, MWW
732.299.7890: sweeks@mww.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
34 minutes ago
- Globe and Mail
Cloudflare Expands AI Tools: Will Revenue Growth Follow?
Cloudflare NET is implementing artificial intelligence (AI) initiatives across its portfolio and experiencing strong traction across AI Gateway, Workers AI and Durable Objects and Containers solutions. In the first quarter of fiscal 2025, NET reported a whopping year-over-year rise of 4,000% in its Workers AI inference requests and a 1,200% increase in AI Gateway requests. Cloudflare is further augmenting its solutions by implementing AI across its infrastructure and security suite. The company has launched the Model Context Protocol server, which is embedded inside the Workers Platform to ease the deployment of AI agents to streamline workflows, handle transactions, and simplify business data queries. This value addition has the potential to increase upsells and customer acquisition. Another recent addition to NET's portfolio is Cloudflare for AI, which is designed to enable businesses to adopt AI responsibly and at scale. The solution includes Data Loss Prevention for AI, which prevents sensitive data from leaking through prompts or model outputs; an AI Gateway, a fully-managed vector database for semantic search named Vectorize and Access for AI with Zero Trust controls. Global giants like Asana, Atlassian, Block, PayPal, Sentry, and Stripe are already working with Cloudflare to create powerful AI experiences. After the implementation of AI capabilities in its portfolio, Cloudflare expects to win several large deals. Cloudflare already had 250,819 paying customers at the end of the first quarter of fiscal 2025, up 27% year over year. NET added 30 new customers during the quarter that contributed more than $100,000 in annual revenues, taking the count of such customers to 3,527 at the end of the quarter. For 2025, Cloudflare anticipates its revenues between $2.09 billion and $2.094 billion. The Zacks Consensus Estimate for the same is pegged at $2.09 billion, indicating a year-over-year rise of 25.38%. How Competitors Fare Against Cloudflare Cloudflare faces competition in multiple dimensions from Amazon AMZN. Amazon Web Services' ('AWS') Lambda, Bedrock, SageMaker, and API Gateway make it a direct competitor of Cloudflare in the serverless computing and AI inference space. AWS also offers vector databases and cybersecurity services like Cloudflare. Alphabet 's GOOGL Vertex AI, Cloud Run, Firebase, and AI/ML APIs, Google Cloud Platform offers solutions for AI development, model inference, and low-latency app deployment, making Alphabet a strong contender for Cloudflare. Cloudflare's AI initiatives have brought it head-on with cloud hyperscalers like Alphabet and Amazon in infrastructure and inference hosting, with enterprises switching to Cloudflare platform for its better performance, lower development cost and modernized platform. These factors will help NET boost its revenues. Cloudflare's Price Performance, Valuation and Estimates Shares of NET have surged 73.2% year to date compared with the Zacks Internet - Software industry's growth of 15.4%. From a valuation standpoint, NET trades at a forward price-to-sales ratio of 27.42X, higher than the industry's average of 5.8X. The Zacks Consensus Estimate for NET's 2025 and 2026 earnings implies year-over-year growth of 5.33% and 31.64%, respectively. The estimates for 2025 and 2026 earnings have been revised downward in the past 60 days and 30 days, respectively. NET currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Cloudflare, Inc. (NET): Free Stock Analysis Report
Globe and Mail
35 minutes ago
- Globe and Mail
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
BMY depends on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy drugs face generic competition. Legacy Portfolio is adversely impacted due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the U.S. Medicare Part D redesign effect. Sales of blood thinner medicine Eliquis were down 4% in the first quarter due to the impact of Medicare Part D redesign in the United States. In such a scenario, the performance of new drugs is key to BMY's growth. Thalassemia drug, Reblozyl, has put up a stellar performance, driven by strong growth in the first and second-line treatment of myelodysplastic syndromes (MDS)-associated anemia. The drug should contribute significantly in the coming decade. Revenue growth has been good for the leading immuno-oncology drug Opdivo, driven primarily by volume growth. Sales of CAR T cell therapy, Breyanzi, also continue to gain traction from the approval of new indications and expanded manufacturing capacity. Camzyos has also witnessed strong global uptake in obstructive HCM. BMY had earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy. The approval broadens BMY's portfolio. Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. This drug is expected to contribute meaningfully to BMY's top line in the coming years. Competition for BMY's Key Drugs Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space. The immuno-oncology space is dominated by pharma giant Merck 's MRK blockbuster drug Keytruda (pembrolizumab). Keytruda is approved for several types of cancer and alone accounts for around 50% of MRK's pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda. Pfizer PFE is one of the largest and most successful drugmakers in the field of oncology. It has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of cancers, including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer. Last month, Pfizer inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China. BMY is also trying to develop bispecific antibodies. BMY's Price Performance, Valuation and Estimates Shares of Bristol Myers have lost 15% year to date compared with the industry 's decline of 3.4%. From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY's shares currently trade at 7.34x forward earnings, lower than its mean of 8.54x and the large-cap pharma industry's 14.79X. The Zacks Consensus Estimate for 2025 and 2026 earnings per share has moved south in the past 60 days. BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
Globe and Mail
an hour ago
- Globe and Mail
Beeline Holdings (NASDAQ: BLNE) Subsidiary Closes Crypto-Backed Real Estate Deal
Beeline Holdings (NASDAQ: BLNE), a digital mortgage platform, announced that its subsidiary Beeline Title Holdings, Inc. has completed what it believes to be one of the first residential real estate closings funded via a cryptocurrency token backed by real property. The milestone marks a significant step in merging blockchain finance with traditional title and escrow services. Beeline aims to expand its crypto-enabled platform to all lenders, offering infrastructure for compliant transaction disbursement and reconciliation. The company plans to launch a fractional equity sale product in August 2025 through Beeline Loans, Inc., with Beeline Title handling closings. To view the full press release, visit About Beeline Financial Holdings, Inc. Beeline Financial Holdings, Inc. is a trailblazing mortgage fintech transforming the way people access property financing. Through its fully digital, AI-powered platform, Beeline delivers a faster, smarter path to home loans—whether for primary residences or investment properties. Headquartered in Providence, Rhode Island, Beeline is reshaping mortgage origination with speed, simplicity, and transparency at its core. The company is a wholly owned subsidiary of Beeline Holdings and also operates Beeline Labs, its innovation arm focused on next-generation lending solutions. NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Corporate Communications
